REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and ...

The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.

在其他近期新闻中，Plus Therapeutics在临床和监管方面取得了重大进展。该公司宣布美国食品药品监督管理局 (FDA)授予其研究性治疗药物Rhenium (186Re) Obisbemeda用于肺癌患者脑膜转移的孤儿药资格。这一资格提供了潜在的市场独占权和税收抵免等好处，增强了公司的开发前景。Plus ...

Ian Everard warns of a looming precious metals supply crunch. He highlights manipulated markets, dwindling silver stocks, and ...

Plus Therapeutics (PSTV) announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Rhenium Obisbemeda for the ...

Shares of Plus Therapeutics, Inc. PSTV were up a whopping 311.4% on March 6 after the company announced that the FDA has ...

A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to ...

Plus Therapeutics (PSTV) announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, having determined an RP2D. The ...

ReSPECT- LM Phase 1 single dose is now complete, and the recommended Phase 2 dose (RP2D) for single administration therapy has been determinedAUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus ...

智通财经APP获悉，Plus Therapeutics (PSTV.US)周四表示，其针对肺癌患者软脑膜转移的治疗药物Rhenium (186Re) Obisbemeda获得美国食品药品监督管理局 (FDA)孤儿药认定。受此提振，该公司股价周四收涨311.43%，盘后续涨超50%。

Plus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung ...